Loading provider…
Loading provider…
Hematology (Internal Medicine) Physician in Detroit, MI
NPI: 1407112162Primary Practice Location
KARMANOS CANCER CENTER
4100 John R St, Detroit, MI
Primary Employer
Wayne Health
waynehealthcares.org
HQ Phone
Get MD Andrew's Phone Numberphone_androidMobile
Get MD Andrew's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 52 | 153 |
| 2 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 40 | 177 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 22 | 74 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 18 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 16 | 20 |
Authors: Ajay Major, Jesus Berdeja, Jagoda Jasielec, Jeffrey Zonder, Andrzej Jakubowiak, Benjamin Derman
Journal: Blood Adv
Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
Authors: Jie Chi, Lois Ayash, Joseph Uberti, Asif Alavi, Abhinav Deol
Publication Date: 2020-04-10
Authors: Lois Ayash, Joseph Uberti, Abhinav Deol, Samer Alkassis
Journal: Leuk Lymphoma
Publication Date: 2023-05-08
Lead Sponsor: Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, DRUG: Ibrutinib
Lead Sponsor: Barbara Ann Karmanos Cancer Institute
Intervention / Treatment: DRUG: loncastuximab tesirine
Lead Sponsor: Barbara Ann Karmanos Cancer Institute
Intervention / Treatment: DRUG: A single "booster" dose of the Moderna mRNA COVID-19 vaccine